Skip to main content
. Author manuscript; available in PMC: 2024 Nov 15.
Published in final edited form as: AIDS. 2023 Aug 9;37(14):2185–2190. doi: 10.1097/QAD.0000000000003686

Figure 1. Antiretroviral concentrations affected by Progestin contraception initiation.

Figure 1.

Figure 1.

Cervicovaginal fluid concentrations of tenofovir, lamivudine and efavirenz were measured from Wek-Cel sponges using LC-MS/MS. The log transformed tenofovir (A), lamivudine (B), and efavirenz (C) concentrations were compared before, 3 days after, and 4 weeks after contraception initiation using general estimating equations. Concentrations between women on depot medroxyprogesterone acetate injectable (red) and levonorgestrel implant (teal) were compared at each visit. There were no significant statistical differences for tenofovir or efavirenz. Mean lamivudine concentrations significantly decreased 37% 1 month after contraception initiation. Mean lamivudine CVF concentrations decreased 41% in women on the levonorgestrel implant post-contraception initiation compared to pre-contraception initiation, but no significant difference for DMPA.

Antiretroviral concentrations in the cervicovaginal fluid before, 3 days after, and 1 month after contraceptive hormone initiation for A) tenofovir, B) lamivudine, and C) efavirenz.